The syngeneic FVBW-17 lung tumor cells used for these studies contain both a G12D KRAS activating mutation and a TP53 inactivating mutation, and have the genetic signature of a classic alkylating agent, with a high tumor mutation burden [11]. This evidence concerns the gene TP53 and neoplasm.